PD-1 (PDCD1) and IL-2Rα (CD25), dual-binding on tumor-specific CD8+ T cells

Class

PD-1-targeted IL-2 mutein bispecific fusion protein (immunocytokine)

Pathway

Immune checkpoint blockade combined with IL-2 pathway activation, reversing T cell exhaustion

PD-1 (programmed cell death protein 1) is an inhibitory receptor expressed on T cells that become chronically activated, particularly within tumors, where persistent antigen exposure drives them into a dysfunctional state called T cell exhaustion. Engagement of PD-1 by its ligands suppresses T cell activity, and blocking this receptor is a well-established strategy for restoring anti-tumor immune function. Interleukin-2 (IL-2) is a cytokine that promotes T cell proliferation and effector function, signaling through a receptor complex that includes IL-2Rα (CD25). This mechanism combines both approaches in a single engineered protein: one arm binds PD-1 on exhausted, tumor-reactive CD8+ T cells, while an attached IL-2 variant engages CD25 on the same cells, delivering a proliferative and reactivating signal specifically to cells already flagged as exhausted and tumor-experienced. The rationale for this dual-binding design is selectivity: systemic IL-2 therapy and untargeted PD-1 blockade each have well-documented limitations, and coupling the two signals onto a single molecule is intended to concentrate immune reactivation on the T cell population most relevant to tumor control, rather than broadly stimulating the immune system. This class of mechanism is relevant across solid tumor types where T cell exhaustion is thought to limit the effectiveness of checkpoint blockade alone.